Our Videos

How does the FDA Modernisation Act 2.0 impact seizure liability testing in drug discovery?

How Does the FDA Modernisation Act 2.0 Impact Seizure Liability Testing in Drug Discovery?

This DDW podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance of evaluating seizure liability.

TSA DDW Image shutterstock 2 1.8 | ApconiX

How a Target Safety Assessment Supports the Drug Development Process Podcast

This Drug Discovery World podcast Professor Ruth Roberts, Co-Founder ApconiX, and Claire Sadler, Project Toxicologist, discuss the benefits of carrying out a target safety assessment (TSA) during drug discovery and development whenever a biological target is going to be modulated.

Bethan and Kim Nanion 1 | ApconiX

The Benefits of Early Ion Channel Screening Podcast

This Drug Discovery World podcast Dr Michael Morton, Director and Co-founder, ApconiX, and Dr Kimberly Rockley of ApconiX discuss the benefits of early ion channel screening. The podcast covers the hERG ion channel and its importance in cardiac safety screening in drug discovery.

video10 | ApconiX

Creating the RIGHT toxicology strategy Learning from the past to shape the future

In this 45-minute interactive virtual discussion on the topic ‘Creating the RIGHT toxicology strategy: Learning from the past to shape the future,’

video7 | ApconiX

An Integrated Approach to cardiac safety and CiPA

This presentation will discuss why cardiac safety is so important during the drug discovery and the importance in this scenario of hERG ion channel and the more recent CiPA initiative.

video2 scaled | ApconiX

The Evolving Role of Ion Channels in Shaping Successful Drug Discovery

This webinar will present the critical role of ion channels in drug discovery, and how this role is evolving. The listener will learn about advances in ion channel biology, experimental technologies and in vitro models, new ion channel ligands, and toxicological considerations.

video9 | ApconiX

Evaluate the Toxicological Risk of Targeting Prolyl-Trna Synthetase, PRS In The Treatment of Malaria.

This presentation discusses work was carried out with MMV the not-for-profit Medicines for Malaria Venture. followed by a summary of the research done around the physiological role of the PRS target.

video1 scaled | ApconiX

Improving Drug Project Success by Understanding Drug Target Safety

Join this educational webinar to learn how target safety assessments (TSAs) are used to determine the potential consequences of modulating a target and provide options on how to assess those risks.

video8 | ApconiX

Do Complex Medicines Present a Different Challenge from a Safety Perspective?

The medicines industry is in a period of change. While small molecule therapeutics still make up 90% of approved medicines, patient expectations are driving the industry towards targeted, precision treatments.

video3 scaled | ApconiX

Making Safety Part of Drug Design

This webinar was part of the Medicines Discovery Catapult Connects series of webinars “Is My Compound Safe?”.   This webinar was recorded at the same time as “How to get your molecule into Humans” presented by Pauline Garner of Sequani.

video4 scaled | ApconiX

Making Safety a Part of Drug Design – Preclinical Safety for Anti-infectives

In this webinar, Claire Sadler discussed the toxicological challenges and pitfalls of antibiotic discovery programs. Potential safety risks are the major reason for terminating a program in early phases of antibiotic drug development.

video5 scaled | ApconiX

Science Driven Design of Preclinical Strategy Case by Case

This presentation was part of Alderley Park’s Science Seminar Series.

video6 scaled | ApconiX

Challenges and Opportunities in Toxicology

Ruth will present lessons learned from >20 years’ experience in the pharmaceutical industry focusing on attrition, prediction and the challenges posed by non-clinical to clinical concordance.